FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:16:236 | Achieving a low disease activity state with a corticosteroid dose of 5 mg or less: observational study with anifrolumab in patients with systemic lupus erythematosus in Italy Alessandra Bortoluzzi1, Fulvia Ceccarelli2, Fabio Leo3, Paola Roccatagliata3, Chiara Tani4, Margherita Zen5 | 1Azienda Ospedaliera Universitaria Sant' Anna di Cona, Università di Ferrara Italy; 2Unità di Reumatologia, Università Sapienza Roma Italy; 3AstraZeneca S.p.a. Milano Italy; 4Università di Pisa e Azienda Ospedaliero Universitaria Pisana, Pisa Italy; 5Dipartimento di Medicina DIMED , Divisione di Reumatologia, Università di Padova, Italy
173 -
PO:26:087 | Rituximab versus glucocorticoids for IgG4-related disease: a European retrospective multi-center study of 167 patients Marco Lanzillotta1, Jens Vikse2, Elisabetta Goni3, Jasmin Mahajne1, Veronica Batani1, Lorenzo Dagna1, Emanuel Della-Torre1 | 1Unit of Immunology, Rheumatology, Allergy, and Rare Disease, IRCCS Ospedale san Raffaele Milano, Italy; 2Department of Rheumatology, Stavanger University Hospital, Stavanger, Norway; 3Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich Germany
160 -
PO:15:208 | Impact of disease control on organ damage accrual in patients with systemic lupus erythematosus with and extra-renal flares: a 12-month single-center longitudinal study Giorgia Capozzo1, Marco Oliva1, Giancarlo Cascarano1, Chiara Cardelli1, Dina Zucchi1, Chiara Stagnaro2, Viola Signorini2, Elena Elefante2, Chiara Tani1, Marta Mosca1. | 1Università di Pisa, Dipartimento di Medicina Clinica e Sperimentale, Pisa, Italy; 2Azienda Ospedaliero Universitaria Pisana, U.O. Reumatologia, Pisa, Italy.
208 -
PO:32:176 | Outcomes of upfront combination vs monotherapy with rituximab or mycophenolate mofetil for systemic sclerosis interstitial lung disease: results from a European Scleroderma Trials and Research cohort study Devis Benfaremo1, Corrado Campochiaro2, Gábor Kumánovics3, Christina Bergmann4, Elisabetta Zanatta5, David Launay6, Serena Guiducci7, Mickael Martin8, Carolina De Souza Müller9, Carlomaurizio Montecucco10, Luc Mouthon11, Gabriella Szucs12, Kastriot Kastrati13, Marie-Elise Truchetet14, Madelon Vonk15, Francesco Del Galdo16, Marco Matucci-Cerinic2, Gianluca Moroncini1, Yannick Allanore17. | 1Department of Clinical and Molecular Sciences, Marche Polytechnic University, Marche University Hospital, Ancona, Italy; 2Vita-Salute San Raffaele University, San Raffaele Hospital, Milano, Italy; 3University of Pécs, Department Of Rheumatology And Immunology, Pécs, Hungary; 4University Hospital Erlangen, Department Internal Medicine 3, Erlangen, Germany; 5Padova University Hospital, Rheumatology Unit, Padova, Italy; 6Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Lille, France; 7University of Florence, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy; 8Poitiers University Hospital, Department of Internal Medicine Poitiers France; 9Hospital de Clinicas da Universidade Federal do Parana Curitiba Brazil; 10Università di Pavia e IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy; 11Hôpital Cochin, Department of Internal Medicine, Paris, France; 12University of Debrecen, Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary; 13Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria; 14CHU de Bordeaux, Rheumatology department, Bordeaux, France; 15Radboudumc, Department of Rheumatology Nijmegen The Netherlands; 16Leeds Raynauds and Scleroderma Program, NIHR Biomedical Research Centre, Leeds, United Kingdom; 17Université Paris Cité, Cochin Hospital, Rheumatology Department, Paris, France.
238 -
PO:16:240 | Systemic Lupus Erythematosus Presenting as End-Stage Liver Disease: A Case Report and Literature Review Annamaria Tiso1, Stefania Caccavelli1, Giuseppina Caroppi1, Candida Tarullo1, Gaetano Serviddio1 | 1Policlinico Riuniti Foggia, Italy
144
